Related references
Note: Only part of the references are listed.HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
S. G. T. Devaraj et al.
LEUKEMIA (2016)
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
K. Akahane et al.
LEUKEMIA (2016)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Baohua Sun et al.
BLOOD (2015)
The identification and characterization of a STAT5 gene signature in hematologic malignancies
Dmitriy Sonkin et al.
CANCER BIOMARKERS (2015)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C. Meyer et al.
CANCER CELL (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Clinical and molecular genetic characterization of myelofibrosis
Gabriela S. Hobbs et al.
CURRENT OPINION IN HEMATOLOGY (2015)
Single-Cell Mass Cytometry Reveals Intracellular Survival/Proliferative Signaling in FLT3-ITD-Mutated AML Stem/Progenitor Cells
Lina Han et al.
CYTOMETRY PART A (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Jae-Seok Roe et al.
MOLECULAR CELL (2015)
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Denes Hnisz et al.
MOLECULAR CELL (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Gregory K. Behbehani et al.
CANCER DISCOVERY (2015)
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong et al.
CELL REPORTS (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer et al.
CLINICAL CANCER RESEARCH (2014)
Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm
Raajit Rampal et al.
CURRENT OPINION IN HEMATOLOGY (2014)
Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
Suhu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
M. A. Dawson et al.
LEUKEMIA (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
Friederike Itzen et al.
NUCLEIC ACIDS RESEARCH (2014)
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Raajit Rampal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Selective targeting of the stress chaperome as a therapeutic strategy
Tony Taldone et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
Jessica E. Bolden et al.
CELL REPORTS (2014)
Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities
Carmen Blanco-Aparicio et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Cristiana Sessa et al.
CLINICAL CANCER RESEARCH (2013)
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Jelena D. Milosevic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Alireza Eghtedar et al.
BLOOD (2012)
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang et al.
BLOOD (2012)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho et al.
BLOOD (2012)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
Madappa N. Kundranda et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation
Sergei Nechaev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2011)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells
Liyun Sang et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Share Paper
